While oncology continues to dominate the pharma investment landscape, neuroscience is an area of opportunity, especially with the unmet medical need for an effective treatment of Alzheimer’s Disease. In spite of lower success rates and high profile exits of some large pharma companies, neuroscience remains an active R&D area, third behind oncology and immune/inflammation. Jamie Munro, Global Practice Leader for Portfolio and Licensing with Clarivate Analytics digs deeper into the investment landscape for neuroscience, looking at deals, M&A, and VC investment. A closer examination of Alzheimer’s disease development, with setbacks and outlook, will also be covered.

Session ID: 413181